The $50,000 Cure Problem: Why the US Can’t Do What India Already Did | Andy Holt & Phil Vanek
A vector core leader and cell therapy investor advisor explain why a sickle cell gene therapy costs $50,000 in India and $4 million in the US — same science, different systems — and why biotech startups should hunt for boring and stop drinking the Kool-Aid when the data says pivot.